IAM Patent 1000 lists Paul-Alexander Wacker among recommended patent experts

Yesterday, Intellectual Asset Management magazine publicly released its 2018 rankings of the IAM Patent 1000, listing Paul-Alexander Wacker among this distinguished class.

Paul-Alexander Wacker has been listed for several consecutive years among the IAM 1000. He now continues his appearance in the listings as of-counsel of Stolmár & Partner.

The IAM Patent 1000 provides a resource for identifying world-class patent attorneys in private practice. The quantitatively-evaluated listings account for depth of knowledge, market presence, level of work, and positive peer and client feedback.

For more information, please see Paul-Alexander Wacker’s  full profile on the IAM 1000 website.

Weiterlesen … IAM Patent 1000 lists Paul-Alexander Wacker among recommended patent experts

Dr. Matthias Stolmár publizierte in Biospektrum 03 2018 einen Artikel über den Widerruf des CRISPR/CAS Grundlagenpatents EP 2 771 468 B1 des Broad Instituts vor dem Europäischen Patentamt.

Zu lesen unter:

https://www.biospektrum.de/blatt/d_bs_pdf&_id=1564662

Weiterlesen … Dr. Matthias Stolmár publizierte in Biospektrum 03 2018 einen Artikel über den Widerruf des CRISPR/CAS Grundlagenpatents EP 2 771 468 B1 des Broad Instituts vor dem Europäischen Patentamt.

Stolmár & Partner opens new office in Hamburg and welcomes Andreas Noack as Hamburg Managing Partner

Stolmár & Partner opens new office in Hamburg and welcomes Andreas Noack as Hamburg Managing Partner

Stolmár & Partner is excited to announce the opening of its Hamburg office. Dr. Matthias Stolmár, Founding and Managing Partner of Stolmár & Partner: “As we continue to grow with domestic clients operating around the world to develop new technology, it is important to be more accessible in Germany. Hamburg is the economic hub of Northern Germany with its industry clusters for aviation, healthcare, life sciences, media & IT and renewable energies.“

Weiterlesen … Stolmár & Partner opens new office in Hamburg and welcomes Andreas Noack as Hamburg Managing Partner

Etappensieg für Generikahersteller: EPA widerruft Dosierungspatent für Bayers Xarelto

Wichtige Entscheidung für Generikahersteller in Sachen Xarelto: Die Einspruchskammer des Europäischen Patentamtes hat das Dosierungspatent des Blutgerinnungshemmers widerrufen. Xarelto ist eines der Blockbustermedikamente des Pharmariesen Bayer. Obwohl die Entscheidung nur die Dosierung und nicht das Stoffpatent betrifft, könnten die Generikahersteller dadurch früher mit eigenen Medikamenten an den Markt gehen. Bayer kann dagegen Berufung einlegen.

Weiterlesen … Etappensieg für Generikahersteller: EPA widerruft Dosierungspatent für Bayers Xarelto

Stolmár & Partner is excited to welcome internationally well-known Patent Attorney Paul-Alexander Wacker as of-counsel advisor in its team on January 1, 2018.

Stolmár & Partner is excited to welcome internationally well-known Patent Attorney Paul-Alexander Wacker as of-counsel advisor in its team on January 1, 2018.

Paul-Alexander Wacker founded the renowned German IP law firm Kuhnen & Wacker in Freising, in the proximity of Munich in 1975 together with Rainer Kuhnen. His long-standing experience in IP and beyond has been sought by high-calibre clients worldwide and even since 2013, when he became “of counsel” to the firm.

Weiterlesen … Stolmár & Partner is excited to welcome internationally well-known Patent Attorney Paul-Alexander Wacker as of-counsel advisor in its team on January 1, 2018.